• Member News

Biosphere businesses receive funding boost to support the global fight against COVID-19

TWO businesses based in The Biosphere on Newcastle Helix have been awarded funding to accelerate their innovations to support the global fight against the COVID-19. Innovate UK, the UK’s innovation agency has awarded ExplantLab and Atelerix almost £50,000 each to fast track their ideas and research.

Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit. This kit is for research use only and launched under the T-SPOT Discovery brand. This research kit could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic, which in turn could help to bring nations out of their current lockdowns in a faster, safer and more controlled manner.

Locate Bio announces the appointment of John von Benecke as CEO

Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, announced that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline.

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield

Discovery Park part of domestic and global response to COVID-19 pandemic

Science Park open for business to support community’s important activities

CiRA Foundation and the Cell and Gene Therapy Catapult set to launch new stem cell collaborative research

The companies will combine their expertise to explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicine products.

AI-based precision medicine mining of UK Biobank finds 13 human COVID risk genes and identifies 59 drugs with potential to improve survival in severe COVID-19 patients and sepsis

• 70 sepsis risk genes identified from UK Biobank, 61% of which are present specifically in severe COVID-19 patients (‘COVID risk genes’) • 13 ‘COVID risk genes’ identified as known druggable targets • 59 compounds and drugs identified with potential for accelerated drug discovery (‘repurposing’) • Study also offers potential for identifying COVID-19 high risk biomarkers

Coulter Partners places Chief Medical Officer for Saniona

Coulter Partners was very pleased to partner recently with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner brings more than 20 years of experience leading multiple pharmaceutical development programs from discovery through approval and launch, in both large and small pharmaceutical companies.

Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy

• OncoSpan range expanded to include FFPE and cfDNA formats to mimic solid tumors and liquid biopsy samples, respectively • Cell-line derived reference standards offer an unlimited and reproducible resource to help ensure consistency during diagnostic assay workflows

Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19

Supporting the race for treatments new collaboration launched to drive understanding of COVID-19 Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19